Duality Advisers LP Makes New $2.78 Million Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Duality Advisers LP bought a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 28,830 shares of the biotechnology company's stock, valued at approximately $2,780,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SRPT. Mizuho Markets Americas LLC bought a new stake in shares of Sarepta Therapeutics in the third quarter valued at about $29,813,000. Westfield Capital Management Co. LP raised its stake in shares of Sarepta Therapeutics by 40.1% during the 3rd quarter. Westfield Capital Management Co. LP now owns 806,400 shares of the biotechnology company's stock worth $97,752,000 after purchasing an additional 230,618 shares in the last quarter. TD Asset Management Inc raised its stake in shares of Sarepta Therapeutics by 377.7% during the 3rd quarter. TD Asset Management Inc now owns 204,626 shares of the biotechnology company's stock worth $24,805,000 after purchasing an additional 161,788 shares in the last quarter. Avidity Partners Management LP grew its stake in shares of Sarepta Therapeutics by 51.3% in the third quarter. Avidity Partners Management LP now owns 450,000 shares of the biotechnology company's stock valued at $54,549,000 after buying an additional 152,500 shares in the last quarter. Finally, abrdn plc acquired a new position in Sarepta Therapeutics during the fourth quarter worth $14,159,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on SRPT shares. Cantor Fitzgerald restated a "neutral" rating and set a $128.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Citigroup boosted their price objective on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a "buy" rating in a research note on Thursday, February 29th. Barclays boosted their price objective on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an "overweight" rating in a research note on Thursday, February 29th. UBS Group boosted their price objective on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a "buy" rating in a research note on Friday, March 1st. Finally, Mizuho upped their price target on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a "buy" rating in a research note on Wednesday, February 14th. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $158.38.

Sarepta Therapeutics Trading Up 1.2 %

Shares of SRPT traded up $1.34 during trading hours on Monday, hitting $116.96. 889,140 shares of the stock were exchanged, compared to its average volume of 984,181. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $159.89. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.95 and a quick ratio of 3.45. The business has a 50-day moving average of $126.32 and a 200-day moving average of $110.26. The firm has a market capitalization of $10.98 billion, a P/E ratio of -19.11 and a beta of 0.94.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.50. The company had revenue of $396.80 million during the quarter, compared to analysts' expectations of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. Sarepta Therapeutics's revenue for the quarter was up 53.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.24) earnings per share. On average, research analysts expect that Sarepta Therapeutics, Inc. will post 2.13 EPS for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the firm's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the transaction, the insider now directly owns 26,836 shares of the company's stock, valued at $3,457,550.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Bilal Arif sold 2,000 shares of the firm's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.84, for a total transaction of $257,680.00. Following the transaction, the insider now directly owns 26,836 shares of the company's stock, valued at $3,457,550.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the firm's stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the transaction, the director now directly owns 22,840 shares in the company, valued at $2,815,030. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,096 shares of company stock valued at $2,739,419. Corporate insiders own 7.40% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.